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One of the factors associated with an increased risk of HPV-related malignant transformation
may be bacterial and/or viral infections. The aim of our study was to examine whether the
presence of infectious agents commonly detected in the genitourinary tract such as
herpesviruses (HSV, CMV), and ureaplasmas (Ureaplasma urealyticum, Ureaplasma
parvum) may lead to alterations in the expression of the HPV-16 E6 oncogene. Quantitative
RT-PCR analysis was used to assess the level of HPV-16 E6 mRNA expression in SiHa cells.
The presence of HSV-1 or HSV-2 in SiHa cells caused a 1.5-fold increase in HPV-16 E6
mRNA expression as compared with non-inoculated SiHa cells. Ureaplasma urealyticum
presence but not Ureaplasma parvum stimulated the expression of HPV-16 E6 resulting in a
nearly five-fold (4.8) up-regulated E6 mRNA level in SiHa cells. Our study is the first to
suggest that infection of Ureaplasma urealyticum in an urogenital tract could increase the
risk of cervical cancer by overexpression of the HPV E6 oncogene.
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Human cervical cancer is the second major type
of cancers for women worldwide. Persistent in-
fection with human papillomavirus, especially
HPV-16, is considered to be a very important risk
factor (ZUR HAUSEN 2002). HPV-mediated tumo-
rigenesis is mainly due to the activities of two viral
oncoproteins: E6 and E7. The expression of E6
and E7 is controlled during the normal viral life cy-
cle when viral DNA replicates extrachromo-
somally. HPV E6 and E7 oncoproteins are
overexpressed when the viral genome integrates
into the host DNA (ZUR HAUSEN 2002; SZOSTEK
et al. 2008). Deregulated overexpression of E6 and
E7 oncoproteins can cause several changes in cel-
lular pathways and functions leading to malignant
transformation of cells and tumorigenesis
(GANGULY & PARIHAR 2009). HPV E7 binds to
hypophosphorylated pRb, preventing its interac-
tion with the E2F transcription factor (DYSON et al.
1998; MUNGER & HOWLEY 2002). During the
normal cell cycle, the pRb protein is active in its
hypophosphorylated form and binds to E2F to pre-
vent S-phase entry. HPV E6 is able to induce the
degradation of p53 by direct binding to the cellular
protein ubiquitin ligase E6AP (E6-associated pro-
tein) (SCHEFFNER et al. 1993). p53 is a well-
known cellular tumor suppressor protein involved
in processes such as DNA repair, chromatin re-
modeling, differentiation, and apoptosis. Neutrali-
zation of p53 tumor suppressor pathways by
increased expression of HPV E6 as well as E7 on-
cogenes can cause disturbances in fundamental cell-
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cycle proteins and may contribute to tumorigene-
sis (SCHEFFNER et al. 1990; WERNESS et al.
1990). Moreover, the high-risk HPV-16 E6 pro-
tein has been reported to prevent apoptosis by
a p53-independent mechanism which involves in-
hibition of Bax gene expression and degradation of
Bax protein in human keratinocytes (MAGAL et al.
2005). Inhibition of the pro-apoptotic protein Bax
results in inhibition of apoptosis and therefore cells
accumulate mutations in their DNA (GANGULY &
PARIHAR 2009). Although the E6 and E7 genes are
necessary for immortilization, and malignant
transformation, they are not sufficient.
A number of factors are associated with an in-
creased risk of HPV-related malignant transfor-
mation, including UV and X-ray radiations,
smoking tobacco, steroid hormones, and probably
bacterial and viral infections. It is worth noting
that studies showing that HSV infection, in con-
junction with HPV infection, may increase the risk
of invasive cervical carcinoma have received
much attention over the years (HILDESHEIM et al.
1991; DIPAOLO et al. 1998; SMITH et al. 2002;
ZHAO et al. 2012). SMITH et al. (2002) performed
a pooled analysis that found prior exposure to
HSV-2 was associated with a 2-fold increased risk
of squamous cell carcinoma of the cervix in pa-
tients with HPV (SMITH et al. 2002). Whereas in
vitro studies suggest that the XhoII subfragment of
the HSV-2 genome is capable of inducing the tu-
morigenic conversion of HPV-immortalized cer-
vical keratinocytes (DIPAOLO et al.1998).
The immediate-early gene products of cytomega-
lovirus (CMV) can transactivate other viral and
cellular genes (TENNEY & COLBERG-POLEY 1991).
At least four HCMV proteins can modulate cell cy-
cle progression by binding to the retinoblastoma
family members, inducing their degradation. It has
been suggested that concurrent genital infection
with CMV and HPV might increase the risk for
cervical cancer (SHEN et al. 1993; SZOSTEK et al.
2009).
Ureaplasmas represent atypical bacteria that
lack cellular membranes, closely adhere to human
epithelial cells and may be associated with
urogenital diseases (ABELE-HORN et al.1997; KIM
et al. 2003; ZDRODOWSKA-STEFANOW et al. 2006;
EKIEL et al. 2009; BIERNAT-SUDOLSKA et al.
2011).
The aim of our study was to examine whether the
presence of infectious agents commonly detected
in the human genitourinary tract such as her-
pesviruses (HSV, CMV), and ureaplasmas (Urea-
plasma urealyticum, Ureaplasma parvum) may
lead to alterations in the expression of HPV-16 E6
in the SiHa cell line.
Material and Methods
Cell cultures
The SiHa cell line is reported to contain an inte-
grated human papillomavirus type 16 (HPV-16) in
1-2 copies per cell. SiHa cells (ATCC: HTB-35)
were cultured in Eagle medium (MEM) (CytoGen,
Germany) supplemented with 10% heat-
inactivated fetal bovine serum (GIBCO, Invitro-
gen), 2 mM L-glutamine, 200 U/mL penicillin,
150 Fg/mL streptomycin (Polfa Tarchomin SA,
Poland). Rabbit kidney cells (RK-13, ATCC:
CCL-37) and human diploid fibroblast cells
(MRC-5, ATCC:CCL-171) were maintained in
the same MEM and were used for propagation of
herpesviruses.
Amounts of 1x106 cells were placed in the flasks
and were incubated in a humidified incubator with
5% CO2 at 37°C.
Preparation of viral and ureaplasma strains
HSV-1 (McIntyre strain; ATCC: VR-539) and
HSV-2 (ATCC VR-734) were grown in a RK-13
cell monolayer. Infected cells were subjected to
three cycles of freezing and thawing and were kept
at -80°C prior to use. Virus titers were determined
in RK-13 cell culture and are expressed as tissue
culture infective dose (TCID50). The CMV strains
Town (ATCC VR-977) and AD169 (ATCC VR-538)
were grown in MRC-5 monolayers. CMV titer was
assessed in MRC-5 cells by the IF method with the
use of monoclonal antibodies CCH2+DDG9 (Dako,
Denmark) specific for viral immediate early and
early proteins and expressed as cell forming unit
(CFU).
Ureaplasma species (U. urealyticum; ATCC 27816,
U. parvum; ATCC 27815) were cultured in liquid
and solid PPLO media according to a procedure
described earlier (BIERNAT-SUDOLSKA et al. 2006).
Liquid media were incubated for 72 hours at 37°C,
while solid media for 5-7 days. The growth of mi-
croorganims on liquid PPLO media caused a col-
our change of the medium (hydrolysis of urea with
the release of ammonia, signalled by a colour
change of a pH indicator), while on solid media it
was the presence of characteristic brownish colo-
nies of ureaplasmas (magnification 125x). Urea-
plasma titers were determined in liquid PPLO me-
dia and expressed as colour changing units (CCU).
Inoculation of SiHa cells
SiHa cells were inoculated separately with six
different pathogens, i.e. one flask of SiHa cell
monolayer for each pathogen was inoculated with
defined doses of studied microorganisms: HSV-1
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at dose of 100 TCID50, HSV-2 at dose of 100
TCID50, CMV Town strain at dose of 100 CFU,
CMV AD169 strain at dose of 100 CFU, 2x105
CCU Ureaplasma parvum, 2x105 CCU Urea-
plasma urealyticum. A non-inoculated SiHa cell
monolayer was used as a control. Each experiment
was performed in five repetitions.
After adsorption of microorganisms to SiHa
cells (60 min. 20oC), unadsorbed viruses or urea-
plasmas were removed by washing of cell mono-
layers with phosphate-buffered saline (PBS). The
cells were covered with maintained medium and
incubated in a humidified incubator with 5% CO2
at 37°C. After 24 hours of incubation, the cells
were harvested and immediately used for RNA
isolation.
Reverse transcription and real-time quantitative
PCR (qRT-PCR)
Total RNA was extracted using Trizol (Invitro-
gen) according to the method of CHOMCZYNSKI &
SACCHI 1987. RNA integrity was judged by elec-
trophoresis and RNA concentration was quantified
by measuring the optical density (OD) at 260 nm.
Measuring the A260 nm/A280 nm ratio (always >1.8)
assessed the nucleic acid purity. RNA samples
were treated with DNase I and reverse-transcribed
into cDNA using Moloney murine leukemia virus
reverse transcriptase (Sigma) with oligo-(dT) primer
(Sigma). Quantitative real-time PCR (qRT-PCR)
was performed using Fast SYBR Master Mix as
a detection dye in an ABI 7500 Fast Real-time
PCR system (Applied Biosystems, Foster City, CA,
USA) and was quantified using the relative quanti-
fication method. The quantity of HPV-16 E6 tran-
scripts in each sample was standardized by
glyceraldehyde3-phosphatedehydrogenase (GAPDH)
transcript level. For HPV-16 E6, the primers were
5’-GACCCAGAAAGTTACCACAG-3’ (forward)
and 5’-CATAAATCCCgAAAAGCAAAG-3’ (re-
verse) and for GAPDH the primers were
5’-CTGCACCACCAACTGCTTAG-3’ (forward)
and 5-TTCTGGGTGGCAGTGATG -3’ (reverse)
(LUCZAK & JAGODZINSKI 2008). For amplifica-
tion, 2Fl of total (20Fl) cDNA solution was added
to 18Fl of Fast SYBR Master Mix (Life Technolo-
gies). Thermal cycling was performed with an ini-
tial denaturation step of 10 s at 95°C, followed by
40 cycles of 3 s at 95°C, and 60°C for 30 s. Real-
time PCR reactions were always set up in triplicate
in order to estimate PCR variation. The qRT-PCR
specificity was assessed on the basis of the melting
temperature for each amplimer. The quantity of
HPV-16 E6 transcripts in each sample was stan-
dardized to GAPDH transcript level. Relative
quantitation of gene expression was performed as
previously described (KANG et al. 2010). Since the
amplification efficiency of HPV-16 E6 and
GAPDH transcripts (as a reference gene) differed,
quantification of copy number of these genes was,
respectively, derived from a different standard
curve for HPV-16 E6 and the reference gene.
Statistical analysis
Serial dilutions from the cDNA SiHa cells were
used to produce standard curves, the quality of
which was assessed by the slope of the standard
curve and the square of the Pearson correlation co-
efficient (R2). The efficiency of the target amplifi-
cation and threshold cycle values (Ct) were
automatically determined by ABI 7500 Fast Real-
time PCR software. Relative expression levels for
E6 HPV-16 versus GAPDH were assessed as
means of five measurements ± 0.95 confidence in-
terval. Expression of E6HPV-16 transcripts in
non-inoculated SiHa cells was assigned a value of 1.
All data were analyzed using STATA 10.0 software.
Correlations were calculated by using an ANOVA
test. A p-value of <0.05 was considered significant.
Results
The qRT-PCR analysis showed the presence of
HPV-16 E6 mRNA in the examined SiHa cells 24
h after inoculation with HSV-1, HSV-2, CMV
Town strain, CMV AD169 strain, Ureaplasma
parvum or Ureaplasma urealyticum. Expression
levels for HPV-16 E6 mRNA were calculated rela-
tive to GAPDH transcripts according to a method
described previously by PFAFFL (2001) using the
standard curves for target and reference genes.
Standard curves of Ct for HPV-16 E6 and GAPDH
versus mRNA copy number indicated linearity and
the R2 values were more than 0.99 (Fig. 1a, 1b).
Figure 2 shows the results obtained from five re-
peated experiments, for each pathogen the level of
E6 HPV-16 expression was assessed 24 hours after
inoculations and it was compared with the level of
E6 HPV-16 mRNA in non-inoculated SiHa cells.
The presence of the pathogens in SiHa cells to-
gether with maintained culture medium after 24
hours post inoculation was confirmed using meth-
ods described in Material and Methods. Although
the titer of each pathogen after 24 hours post in-
oculation was lower by approximately 1-2 log than
at the time of inoculation, all studied microorgan-
isms were still viable. The level of HPV-16 E6
mRNA expression in the examined SiHa cells 24h
after inoculation by HSV-1, HSV-2, Ureaplasma
parvum or Ureaplasma urealyticum was higher,
1.4 ± 0.25, 1.5 ± 0.32, 1.1 ± 0.16 and 4.8 ±1.31 fold
respectively, as compared to non-inoculated SiHa
cells, but the difference was statistically significant
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Fig. 1. Standard curves of quantitative real-time PCR  amplification transcripts of: A. HPV-16 E6 oncogene;
B. glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Serial dilutions of cDNA SiHa cells (containing an integrated
HPV-16) were performed for quantification experiments. The curve equations, efficiency values (E) and square of the Pearson
correlation coefficient (R2) were plotted.
Fig. 2. Relative expression of HPV-16 E6 mRNA in SiHa cells before and 24h after inoculation with HSV-1, HSV-2, CMV
Town strain or CMV AD169 strain, Ureaplasma parvum (Up), Ureaplasma urealyticum (Uu) in non-inoculated SiHa cells
(control). Gene expression levels were calculated by the relative standard curve method. Values are means ± 0.95 confidence
interval. The significance of difference for the amount of HPV-16 E6 mRNA expression was determined by ANOVA
(P=0.02).
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only for Ureaplasma urealyticum (Kruskal-Wallis
test, P=0.02). The qRT-PCR results showed a re-
duction of HPV-16 E6 mRNA transcript levels af-
ter incubating the SiHa cells with CMV AD-169
strain but this effect was not statistically signifi-
cant (Fig. 2).
Discussion
As early as the late sixties of the 20th century, it was
suggested that HSV is associated with cervical can-
cer (RAWLS et al. 1968). Women testing positive
for HSV-2 antibodies were found to have a 60%
increased risk of cervical cancer compared with
seronegative women (HILDESHEIM et al. 1991).
Our results showed that the presence of HSV-1
or HSV-2 in SiHa cells increases (1.5-fold) in
HPV-16 E6 mRNA expression, however, com-
pared to non-inoculated SiHa cells, it is not statisti-
cally significant. The results obtained by other
authors in another model system demonstrated
that the level of transcription of E1, E2 and E6
genes was up to 3-fold enhanced after HSV-2 in-
oculation (PISANI et al. 2004). The authors used
CaSki cells which contained 60 to 600 copies of
HPV-16 DNA per cell and perhaps more copies of
the virus genome in the cell is affected by the dif-
ferences in our results. The same authors in a pre-
vious study in HeLa cells revealed an increase of
HPV18 E1 and E6 mRNA resulting in 9-fold and
3-fold increased transcription, respectively,
twenty hours post HSV-2 infection (PISANI et al.
2002). However, in vitro double infection in A431
and CaSki cells and also vaginal epithelial xeno-
graft model analyses demonstrated that HSV-2 in-
fection down-regulates HPV-11 and HPV-16
transcripts (FANG et al. 2003). To date, a few stud-
ies have investigated the effect of HSV-1 infection
on HPV gene expression in vitro and/or in vivo
models (KARLEN et al. 1993; MEYERS et al.
2003). HSV-1 infection down-regulated HPV-18
E6 transcripts in HeLa cells (KARLEN et al. 1993)
and HPV-31b E2, E6, and E7 mRNA in
CIN-6129E raft tissue (MEYERS et al. 2003).
A study of the cervical exfoliative cells by real-
time PCR revealed that the presence of HSV-2 and
HPV coinfection was much higher in cervical in-
traepithelial neoplasia and squamous cell carci-
noma than in healthy women, OR 34.2 and OR
61.1 respectively. The authors conclude that HSV-2
infection or coinfection with HPVs may be of im-
portance in the development of cervical neoplasias
(ZHAO et al. 2012). However, others do not con-
firm the above conclusions (TRAN-THANH et al.
2003; ZEREU et al. 2007).
In our study the presence of Ureaplasma urea-
lyticum stimulated the expression of HPV-16 E6
resulting in almost five-fold (4.8) increases in E6
mRNA levels in SiHa cells. To our knowledge
these results are the first to suggest that Urea-
plasma urealyticum infection of the urogenital
tract could increase the risk of cervical cancer by
overexpression of the HPV E6 oncogene.
Ureaplasmas as cervicovaginal microorganisms
have been studied as risk factors interacting with
HPV in the development of precancerous and can-
cerous lesions of the uterine cervix (LUKIC et al.
2006; BIERNAT-SUDOLSKA et al. 2011). It is
known that as a member of the Mycoplasmataceae
family, Ureaplasma is comprised of two species
and 14 serovars. Serovars 1, 3, 6 and 14 were clas-
sified as Ureaplasma parvum species and serovars
2, 4, 5, 7-13 as Ureaplasma urealyticum. All urea-
plasmas, the smallest self-replicating organisms
capable of a cell-free existence and lacking cell
walls, are characterized by the possibility of urea
hydrolysis to generate ATP and by adherence to
human mucous membranes. Ureaplasma urealyti-
cum and Ureaplasma parvum are commensals and
pathogens of the human urogenital tract and of
newborn infants. In a previous study we showed
that with concomitant Ureaplasma urealyticum
infection, the risk of HPV infection was 4.7-fold
(p<0.001, 95 % CI: 1.362031-3.507517) greater
than in its the absence. However in the case of
Ureaplasma parvum we did not observe such a re-
lationship (BIERNAT-SUDOLSKA et al. 2011). It
was reported that Ureaplasma urealyticum was
significantly more common in women with high
oncogenic HPV infection and occurred more fre-
quently in women with squamous intraepithelial
lesions (LUKIC et al. 2006; EKIEL et al. 2009). In-
terestingly, a study on the most numerous probi-
otic, Bifidobacterium adolescentis SPM1005-A,
showed a reduction of the level of HPV-16 E6 and
E7 mRNA expression in examined SiHa cells. The
authors suggested that Bifidobacterium adolescen-
tis SPM1005-A had antiviral activity through sup-
pression of E6 and E7 oncogene expression and
could potentially be applied in HPV-associated
cervical cancer prevention (CHA et al. 2012).
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